SlideShare a Scribd company logo
1 of 1
Download to read offline
ACKNOWLEDGEMENTS
55%
60%
65%
70%
75%
80%
STAGE 1 STAGE 2 STAGE 3
ANEURYSM GROWTH STAGE
REDUCTIONINRMS
VELOCITYMAGNITUDE
2 mL/s 3 mL/s 4 mL/s
REFERENCES
COMPUTATIONAL EXAMINATION OF HEMODYNAMIC EFFECTS IN A PATIENT-SPECIFIC GROWING
CEREBRAL ANEURYSM BEFORE AND AFTER VIRTUAL TREATMENT WITH A PIPELINE
EMBOLIZATION DEVICE
Chad Hyslop1, Priya Nair1, Matthew Mortensen1,2, Jonathan Placencia1, David Frakes1,2,3
1SBHSE, Arizona State University, Tempe, AZ 85287; 2EndoVantage, LLC, Scottsdale, AZ 85257; 3ECEE, Arizona State University, Tempe, AZ 85287
Cerebral aneurysms (CAs) are pathological dilatations of a weakened region in the arterial blood vessel wall in the
brain.[1] On average, there is a CA rupturing every 18 minutes in the United States, leading to fatalities in
approximately 40% of cases. Out of the other 60%, 4 out of 7 of these people will have disabilities.[2] Even though CA
treatment by endovascular coiling is considered to be the gold standard by many clinicians, certain complications,
such as coil herniation into the parent vessel, are more likely to occur when treating wide-necked CAs (aneurysms
with a dome-to-neck ratio of < 2). Consequently, flow diversion devices have been developed to avoid these
complications by placing a low porosity mesh-like stent along the parent vessel covering the aneurysm neck. The
function of these devices is to divert flow from entering into the aneurysm, creating blood stasis to allow for intra-
aneurysmal thrombosis. In conventional clinical practice, the impact of hemodynamics on CA progression and
treatment timing are considered only to a limited degree during CA evaluation due to lack of patient-specific flow
information and treatment modeling. Fortunately, emerging applications of novel finite element modeling (FEM) of
endovascular devices coupled with computational fluid dynamics (CFD) now have the potential to predict treatment
effects in the clinical setting. This study investigates the effects of hemodynamics in a patient-specific, wide-necked,
growing CA model before and after virtual treatment with a Pipeline Embolization Device (PED), and compares the
changes in post-treatment blood flow between three stages of aneurysmal growth.
STEP 1: Computational Model Creation
[1] Lasheras, JC., 2007.
[2] Brain Aneurysm Foundation.
http://www.bafound.org/Statistics_and_Facts
Justin Ryan, Ph.D., Research Scientist, Phoenix
Children’s Hospital, Phoenix, AZ
Michael Caplan, Ph.D., Associate Professor, SBHSE,
Arizona State University, Tempe, AZ
Brian W. Chong, M.D., Consultant, Departments of
Radiology and Neurosurgery, Mayo Clinic Hospital,
Phoenix, AZ
EndoVantage, LLC, Scottsdale, AZ
Image Processing Applications Laboratory, SBHSE,
Arizona State University, Tempe, AZ
STEP 2: Virtual Device Deployment
STEP 3: CFD Simulations
Fluid and device domains were discretized into
tetrahedral mesh elements using Ansys ICEM
(ANSYS, Inc., Canonsburg, Pennsylvania USA).
Simulations were performed in Ansys FLUENT
where blood was assumed to be incompressible and
Newtonian, and the model and the device were
assumed to be rigid with no-slip condition imposed at
the walls.
Steady-state inflow rates of 2, 3, and 4 mL/s were
explored, before and after virtual treatment.
STEP 4: Analysis
Simulation results were analyzed using Tecplot 360.
Root-mean-squared (RMS) velocity magnitude,
average pressure, and average wall shear stress (WSS)
were calculated over the aneurysmal domain.
RESULTSINTRODUCTION
Figure 1 - Computational model construction process for a
patient-specific CA: (a) CT image data set, (b) segmentation
and reconstruction, (c) extrusion of inlet and outlet vessels,
and smoothing of 3D computational model.
METHODS
CONCLUSIONS
After PED deployment, the CFD results showed lower RMS velocity magnitude, average pressure, and average
WSS in stage 1 as compared to stages 2 and 3 at steady inflow rates of 3 and 4 mL/s.
The impinging flow jet was noticeably disbursed after PED deployment and velocity magnitudes were visually
reduced within the aneurysm (Figure 5).
The observations made here with respect to PED treatment suggest that treating the aneurysm earlier is more
effective in terms of aneurysmal hemodynamic reductions.
In the clinical setting, this information may be useful during CA evaluation and in determining when the optimal
time is to treat the CA.
Figure 5 - Streamtraces, color-coded by velocity
magnitude, at 3 mL/s steady-state inflow rate for (top)
untreated and (bottom) treated cases.
Figure 3 – Pressure distributions at 3 mL/s steady state-
inflow rate for (top) untreated and (bottom) treated cases.
Treated cases result in 39%, 23%, & 22% reduction in
aneurysmal pressureavg at stages 1, 2, & 3, respectively.
STAGE 1 STAGE 2 STAGE 3
UNTREATEDTREATED
STAGE 1 STAGE 2 STAGE 3
UNTREATEDTREATED
Figure 2 – Computational aneurysm models virtually
treated with PED using device specific FEM models
available in EVIS software (EndoVantage, LLC).
STAGE 1 STAGE 2 STAGE 3
DNR = 1.174DNR = 1.060 DNR = 1.065
ICA Inlet
Outlet PCA Outlet
Aneurysm
PED Figure 6 - Percentage reductions in aneurysmal RMS
velocity magnitude with respect to the untreated models
for each growth stage under conditions of 2, 3, and 4
mL/s steady-state inflow rate.
STAGE 3STAGE 1 STAGE 2
UNTREATEDTREATED
Velocity
Magnitude
(m/s)
Figure 4 - WSS distributions at 3 mL/s steady-state inflow
rate for (top) untreated and (bottom) treated cases.
Treated cases result in 86%, 83%, & 82% reduction in
aneurysmal WSSavg at stages 1, 2, & 3, respectively.
The ICA Inlet has been omitted from all views in Figures 3 and 4 for clarity purposes, however, a small portion of
the ICA inlet is shown in Figure 5 so as to reveal the stream traces.
Stage 1 is at 49 years of age, stage 2 is 445 days post stage 1, and stage 3 is 759 days post stage 2.
(a) (b) (c)

More Related Content

What's hot

Wyniki leczenia przezskónego asd - prof. Jacek Białkowski
Wyniki leczenia przezskónego asd - prof. Jacek BiałkowskiWyniki leczenia przezskónego asd - prof. Jacek Białkowski
Wyniki leczenia przezskónego asd - prof. Jacek Białkowskipiodof
 
Snm 09 Presentation Hkb
Snm 09 Presentation HkbSnm 09 Presentation Hkb
Snm 09 Presentation HkbHBack
 
Perfusion and dynamic contrast enhanced mri
Perfusion and dynamic contrast enhanced mriPerfusion and dynamic contrast enhanced mri
Perfusion and dynamic contrast enhanced mrifahad shafi
 
Coronary Stent thrombosis,comparisons between stents.Bioreabsorbable vascular...
Coronary Stent thrombosis,comparisons between stents.Bioreabsorbable vascular...Coronary Stent thrombosis,comparisons between stents.Bioreabsorbable vascular...
Coronary Stent thrombosis,comparisons between stents.Bioreabsorbable vascular...Dr.Hasan Mahmud
 
Bioabsorbable Drug-Eluting Cardiac Stent Analysis
Bioabsorbable Drug-Eluting Cardiac Stent AnalysisBioabsorbable Drug-Eluting Cardiac Stent Analysis
Bioabsorbable Drug-Eluting Cardiac Stent AnalysisUniversity of Toronto
 
Hybrid procedures – from boxing ring to synchronized
Hybrid procedures – from boxing ring to synchronizedHybrid procedures – from boxing ring to synchronized
Hybrid procedures – from boxing ring to synchronizedArindam Pande
 
Cardiac Pet Power Point
Cardiac Pet Power PointCardiac Pet Power Point
Cardiac Pet Power PointELITE IMAGING
 
SWI for radiation technologists
SWI for radiation technologistsSWI for radiation technologists
SWI for radiation technologistsshokoofeh mousavi
 
In stent neoatherosclerosis
In stent neoatherosclerosis In stent neoatherosclerosis
In stent neoatherosclerosis Kunal Mahajan
 
Unresolved Issues In Myocardial Viability
Unresolved Issues In Myocardial ViabilityUnresolved Issues In Myocardial Viability
Unresolved Issues In Myocardial ViabilityMuhammad Ayub
 
Myocardial viability
Myocardial viability  Myocardial viability
Myocardial viability Prithvi Puwar
 
Role of intraoperative angiography in vascular surgery
Role of intraoperative angiography in vascular surgeryRole of intraoperative angiography in vascular surgery
Role of intraoperative angiography in vascular surgeryJunish Bagga
 
art%3A10.1007%2Fs10237-015-0729-2 (5)
art%3A10.1007%2Fs10237-015-0729-2 (5)art%3A10.1007%2Fs10237-015-0729-2 (5)
art%3A10.1007%2Fs10237-015-0729-2 (5)Desmond Dillon-Murphy
 
Novel paclitaxel coated balloon - dr Piotr Buszman
Novel paclitaxel coated balloon - dr Piotr BuszmanNovel paclitaxel coated balloon - dr Piotr Buszman
Novel paclitaxel coated balloon - dr Piotr Buszmanpiodof
 
Ihab tips and tricks in nuclear cardiology 2019
Ihab tips and tricks in nuclear  cardiology 2019Ihab tips and tricks in nuclear  cardiology 2019
Ihab tips and tricks in nuclear cardiology 2019hospital
 
Ischaemic cardiomyopathy revascularisation how when and why
Ischaemic cardiomyopathy  revascularisation how when and whyIschaemic cardiomyopathy  revascularisation how when and why
Ischaemic cardiomyopathy revascularisation how when and whycardiositeindia
 

What's hot (20)

Wyniki leczenia przezskónego asd - prof. Jacek Białkowski
Wyniki leczenia przezskónego asd - prof. Jacek BiałkowskiWyniki leczenia przezskónego asd - prof. Jacek Białkowski
Wyniki leczenia przezskónego asd - prof. Jacek Białkowski
 
Snm 09 Presentation Hkb
Snm 09 Presentation HkbSnm 09 Presentation Hkb
Snm 09 Presentation Hkb
 
Perfusion and dynamic contrast enhanced mri
Perfusion and dynamic contrast enhanced mriPerfusion and dynamic contrast enhanced mri
Perfusion and dynamic contrast enhanced mri
 
Nuclear cardiology
Nuclear cardiologyNuclear cardiology
Nuclear cardiology
 
Coronary Stent thrombosis,comparisons between stents.Bioreabsorbable vascular...
Coronary Stent thrombosis,comparisons between stents.Bioreabsorbable vascular...Coronary Stent thrombosis,comparisons between stents.Bioreabsorbable vascular...
Coronary Stent thrombosis,comparisons between stents.Bioreabsorbable vascular...
 
Bioabsorbable Drug-Eluting Cardiac Stent Analysis
Bioabsorbable Drug-Eluting Cardiac Stent AnalysisBioabsorbable Drug-Eluting Cardiac Stent Analysis
Bioabsorbable Drug-Eluting Cardiac Stent Analysis
 
Hybrid procedures – from boxing ring to synchronized
Hybrid procedures – from boxing ring to synchronizedHybrid procedures – from boxing ring to synchronized
Hybrid procedures – from boxing ring to synchronized
 
Nuclear imaging bck
Nuclear imaging bckNuclear imaging bck
Nuclear imaging bck
 
Cardiac Pet Power Point
Cardiac Pet Power PointCardiac Pet Power Point
Cardiac Pet Power Point
 
SWI for radiation technologists
SWI for radiation technologistsSWI for radiation technologists
SWI for radiation technologists
 
In stent neoatherosclerosis
In stent neoatherosclerosis In stent neoatherosclerosis
In stent neoatherosclerosis
 
Unresolved Issues In Myocardial Viability
Unresolved Issues In Myocardial ViabilityUnresolved Issues In Myocardial Viability
Unresolved Issues In Myocardial Viability
 
Myocardial viability
Myocardial viability  Myocardial viability
Myocardial viability
 
Role of intraoperative angiography in vascular surgery
Role of intraoperative angiography in vascular surgeryRole of intraoperative angiography in vascular surgery
Role of intraoperative angiography in vascular surgery
 
In stent restenosis
In stent restenosisIn stent restenosis
In stent restenosis
 
art%3A10.1007%2Fs10237-015-0729-2 (5)
art%3A10.1007%2Fs10237-015-0729-2 (5)art%3A10.1007%2Fs10237-015-0729-2 (5)
art%3A10.1007%2Fs10237-015-0729-2 (5)
 
Novel paclitaxel coated balloon - dr Piotr Buszman
Novel paclitaxel coated balloon - dr Piotr BuszmanNovel paclitaxel coated balloon - dr Piotr Buszman
Novel paclitaxel coated balloon - dr Piotr Buszman
 
Ihab tips and tricks in nuclear cardiology 2019
Ihab tips and tricks in nuclear  cardiology 2019Ihab tips and tricks in nuclear  cardiology 2019
Ihab tips and tricks in nuclear cardiology 2019
 
Ischaemic cardiomyopathy revascularisation how when and why
Ischaemic cardiomyopathy  revascularisation how when and whyIschaemic cardiomyopathy  revascularisation how when and why
Ischaemic cardiomyopathy revascularisation how when and why
 
BVS IN STEMI
BVS IN STEMIBVS IN STEMI
BVS IN STEMI
 

Similar to Chad Hyslop - Applied Project Poster_Final

3D CFD simulation of intracranial aneurysm
3D CFD simulation of intracranial aneurysm3D CFD simulation of intracranial aneurysm
3D CFD simulation of intracranial aneurysmwalshb88
 
A1 Project Poster 2016-General Template
A1 Project Poster 2016-General TemplateA1 Project Poster 2016-General Template
A1 Project Poster 2016-General TemplateXianqi Yuan
 
First report of the resolute onyx
First report of the resolute onyxFirst report of the resolute onyx
First report of the resolute onyxIqbal Dar
 
Mechanical thrombectomy in acute stroke [Autosaved].pptx
Mechanical thrombectomy in acute stroke [Autosaved].pptxMechanical thrombectomy in acute stroke [Autosaved].pptx
Mechanical thrombectomy in acute stroke [Autosaved].pptxNeurologyKota
 
Neurosurgical management of ischemic stroke
Neurosurgical management of ischemic strokeNeurosurgical management of ischemic stroke
Neurosurgical management of ischemic strokeDrkedirDekebi
 
Brain AVM (ArterioVenous Malformation) Managment.pptx
Brain AVM (ArterioVenous Malformation) Managment.pptxBrain AVM (ArterioVenous Malformation) Managment.pptx
Brain AVM (ArterioVenous Malformation) Managment.pptxDr. Rahul Jain
 
Hemodynamic assessment of partial mechanical circulatory support: data derive...
Hemodynamic assessment of partial mechanical circulatory support: data derive...Hemodynamic assessment of partial mechanical circulatory support: data derive...
Hemodynamic assessment of partial mechanical circulatory support: data derive...Paul Schoenhagen
 
Ajc d-16-02353 r1 (2)
Ajc d-16-02353 r1 (2)Ajc d-16-02353 r1 (2)
Ajc d-16-02353 r1 (2)Jess Rames
 
HDMICS WSS Koutsiaris 2007
HDMICS WSS Koutsiaris 2007HDMICS WSS Koutsiaris 2007
HDMICS WSS Koutsiaris 2007Koutsiaris Aris
 
AUTOMATED SEGMENTATION OF FLUORESCENT AND FUNDS IMAGES BASED ON RETINAL BLOOD...
AUTOMATED SEGMENTATION OF FLUORESCENT AND FUNDS IMAGES BASED ON RETINAL BLOOD...AUTOMATED SEGMENTATION OF FLUORESCENT AND FUNDS IMAGES BASED ON RETINAL BLOOD...
AUTOMATED SEGMENTATION OF FLUORESCENT AND FUNDS IMAGES BASED ON RETINAL BLOOD...acijjournal
 
AUTOMATED SEGMENTATION OF FLUORESCENT AND FUNDS IMAGES BASED ON RETINAL BLOOD...
AUTOMATED SEGMENTATION OF FLUORESCENT AND FUNDS IMAGES BASED ON RETINAL BLOOD...AUTOMATED SEGMENTATION OF FLUORESCENT AND FUNDS IMAGES BASED ON RETINAL BLOOD...
AUTOMATED SEGMENTATION OF FLUORESCENT AND FUNDS IMAGES BASED ON RETINAL BLOOD...acijjournal
 
Myocardial triglyceride Cardiac Amyloidosis MR Spectroscopy
Myocardial triglyceride Cardiac Amyloidosis MR SpectroscopyMyocardial triglyceride Cardiac Amyloidosis MR Spectroscopy
Myocardial triglyceride Cardiac Amyloidosis MR SpectroscopyPRAMOD KUMAR
 

Similar to Chad Hyslop - Applied Project Poster_Final (20)

CTO and bifurcation
CTO and bifurcationCTO and bifurcation
CTO and bifurcation
 
3D CFD simulation of intracranial aneurysm
3D CFD simulation of intracranial aneurysm3D CFD simulation of intracranial aneurysm
3D CFD simulation of intracranial aneurysm
 
A1 Project Poster 2016-General Template
A1 Project Poster 2016-General TemplateA1 Project Poster 2016-General Template
A1 Project Poster 2016-General Template
 
First report of the resolute onyx
First report of the resolute onyxFirst report of the resolute onyx
First report of the resolute onyx
 
Frank Gijsen
Frank GijsenFrank Gijsen
Frank Gijsen
 
Koutsiaris 2013_a
Koutsiaris 2013_aKoutsiaris 2013_a
Koutsiaris 2013_a
 
Fluckiger_myo_sat
Fluckiger_myo_satFluckiger_myo_sat
Fluckiger_myo_sat
 
Mechanical thrombectomy in acute stroke [Autosaved].pptx
Mechanical thrombectomy in acute stroke [Autosaved].pptxMechanical thrombectomy in acute stroke [Autosaved].pptx
Mechanical thrombectomy in acute stroke [Autosaved].pptx
 
Neurosurgical management of ischemic stroke
Neurosurgical management of ischemic strokeNeurosurgical management of ischemic stroke
Neurosurgical management of ischemic stroke
 
Brain AVM (ArterioVenous Malformation) Managment.pptx
Brain AVM (ArterioVenous Malformation) Managment.pptxBrain AVM (ArterioVenous Malformation) Managment.pptx
Brain AVM (ArterioVenous Malformation) Managment.pptx
 
Hemodynamic assessment of partial mechanical circulatory support: data derive...
Hemodynamic assessment of partial mechanical circulatory support: data derive...Hemodynamic assessment of partial mechanical circulatory support: data derive...
Hemodynamic assessment of partial mechanical circulatory support: data derive...
 
Poster Template
Poster TemplatePoster Template
Poster Template
 
Ajc d-16-02353 r1 (2)
Ajc d-16-02353 r1 (2)Ajc d-16-02353 r1 (2)
Ajc d-16-02353 r1 (2)
 
Stroke-2014
Stroke-2014Stroke-2014
Stroke-2014
 
HDMICS WSS Koutsiaris 2007
HDMICS WSS Koutsiaris 2007HDMICS WSS Koutsiaris 2007
HDMICS WSS Koutsiaris 2007
 
Multi-modal CT scanning in the evaluation of cerebrovascular disease patients
Multi-modal CT scanning in the evaluation of cerebrovascular disease patientsMulti-modal CT scanning in the evaluation of cerebrovascular disease patients
Multi-modal CT scanning in the evaluation of cerebrovascular disease patients
 
AUTOMATED SEGMENTATION OF FLUORESCENT AND FUNDS IMAGES BASED ON RETINAL BLOOD...
AUTOMATED SEGMENTATION OF FLUORESCENT AND FUNDS IMAGES BASED ON RETINAL BLOOD...AUTOMATED SEGMENTATION OF FLUORESCENT AND FUNDS IMAGES BASED ON RETINAL BLOOD...
AUTOMATED SEGMENTATION OF FLUORESCENT AND FUNDS IMAGES BASED ON RETINAL BLOOD...
 
AUTOMATED SEGMENTATION OF FLUORESCENT AND FUNDS IMAGES BASED ON RETINAL BLOOD...
AUTOMATED SEGMENTATION OF FLUORESCENT AND FUNDS IMAGES BASED ON RETINAL BLOOD...AUTOMATED SEGMENTATION OF FLUORESCENT AND FUNDS IMAGES BASED ON RETINAL BLOOD...
AUTOMATED SEGMENTATION OF FLUORESCENT AND FUNDS IMAGES BASED ON RETINAL BLOOD...
 
Myocardial triglyceride Cardiac Amyloidosis MR Spectroscopy
Myocardial triglyceride Cardiac Amyloidosis MR SpectroscopyMyocardial triglyceride Cardiac Amyloidosis MR Spectroscopy
Myocardial triglyceride Cardiac Amyloidosis MR Spectroscopy
 
Ffr ppt
Ffr pptFfr ppt
Ffr ppt
 

Chad Hyslop - Applied Project Poster_Final

  • 1. ACKNOWLEDGEMENTS 55% 60% 65% 70% 75% 80% STAGE 1 STAGE 2 STAGE 3 ANEURYSM GROWTH STAGE REDUCTIONINRMS VELOCITYMAGNITUDE 2 mL/s 3 mL/s 4 mL/s REFERENCES COMPUTATIONAL EXAMINATION OF HEMODYNAMIC EFFECTS IN A PATIENT-SPECIFIC GROWING CEREBRAL ANEURYSM BEFORE AND AFTER VIRTUAL TREATMENT WITH A PIPELINE EMBOLIZATION DEVICE Chad Hyslop1, Priya Nair1, Matthew Mortensen1,2, Jonathan Placencia1, David Frakes1,2,3 1SBHSE, Arizona State University, Tempe, AZ 85287; 2EndoVantage, LLC, Scottsdale, AZ 85257; 3ECEE, Arizona State University, Tempe, AZ 85287 Cerebral aneurysms (CAs) are pathological dilatations of a weakened region in the arterial blood vessel wall in the brain.[1] On average, there is a CA rupturing every 18 minutes in the United States, leading to fatalities in approximately 40% of cases. Out of the other 60%, 4 out of 7 of these people will have disabilities.[2] Even though CA treatment by endovascular coiling is considered to be the gold standard by many clinicians, certain complications, such as coil herniation into the parent vessel, are more likely to occur when treating wide-necked CAs (aneurysms with a dome-to-neck ratio of < 2). Consequently, flow diversion devices have been developed to avoid these complications by placing a low porosity mesh-like stent along the parent vessel covering the aneurysm neck. The function of these devices is to divert flow from entering into the aneurysm, creating blood stasis to allow for intra- aneurysmal thrombosis. In conventional clinical practice, the impact of hemodynamics on CA progression and treatment timing are considered only to a limited degree during CA evaluation due to lack of patient-specific flow information and treatment modeling. Fortunately, emerging applications of novel finite element modeling (FEM) of endovascular devices coupled with computational fluid dynamics (CFD) now have the potential to predict treatment effects in the clinical setting. This study investigates the effects of hemodynamics in a patient-specific, wide-necked, growing CA model before and after virtual treatment with a Pipeline Embolization Device (PED), and compares the changes in post-treatment blood flow between three stages of aneurysmal growth. STEP 1: Computational Model Creation [1] Lasheras, JC., 2007. [2] Brain Aneurysm Foundation. http://www.bafound.org/Statistics_and_Facts Justin Ryan, Ph.D., Research Scientist, Phoenix Children’s Hospital, Phoenix, AZ Michael Caplan, Ph.D., Associate Professor, SBHSE, Arizona State University, Tempe, AZ Brian W. Chong, M.D., Consultant, Departments of Radiology and Neurosurgery, Mayo Clinic Hospital, Phoenix, AZ EndoVantage, LLC, Scottsdale, AZ Image Processing Applications Laboratory, SBHSE, Arizona State University, Tempe, AZ STEP 2: Virtual Device Deployment STEP 3: CFD Simulations Fluid and device domains were discretized into tetrahedral mesh elements using Ansys ICEM (ANSYS, Inc., Canonsburg, Pennsylvania USA). Simulations were performed in Ansys FLUENT where blood was assumed to be incompressible and Newtonian, and the model and the device were assumed to be rigid with no-slip condition imposed at the walls. Steady-state inflow rates of 2, 3, and 4 mL/s were explored, before and after virtual treatment. STEP 4: Analysis Simulation results were analyzed using Tecplot 360. Root-mean-squared (RMS) velocity magnitude, average pressure, and average wall shear stress (WSS) were calculated over the aneurysmal domain. RESULTSINTRODUCTION Figure 1 - Computational model construction process for a patient-specific CA: (a) CT image data set, (b) segmentation and reconstruction, (c) extrusion of inlet and outlet vessels, and smoothing of 3D computational model. METHODS CONCLUSIONS After PED deployment, the CFD results showed lower RMS velocity magnitude, average pressure, and average WSS in stage 1 as compared to stages 2 and 3 at steady inflow rates of 3 and 4 mL/s. The impinging flow jet was noticeably disbursed after PED deployment and velocity magnitudes were visually reduced within the aneurysm (Figure 5). The observations made here with respect to PED treatment suggest that treating the aneurysm earlier is more effective in terms of aneurysmal hemodynamic reductions. In the clinical setting, this information may be useful during CA evaluation and in determining when the optimal time is to treat the CA. Figure 5 - Streamtraces, color-coded by velocity magnitude, at 3 mL/s steady-state inflow rate for (top) untreated and (bottom) treated cases. Figure 3 – Pressure distributions at 3 mL/s steady state- inflow rate for (top) untreated and (bottom) treated cases. Treated cases result in 39%, 23%, & 22% reduction in aneurysmal pressureavg at stages 1, 2, & 3, respectively. STAGE 1 STAGE 2 STAGE 3 UNTREATEDTREATED STAGE 1 STAGE 2 STAGE 3 UNTREATEDTREATED Figure 2 – Computational aneurysm models virtually treated with PED using device specific FEM models available in EVIS software (EndoVantage, LLC). STAGE 1 STAGE 2 STAGE 3 DNR = 1.174DNR = 1.060 DNR = 1.065 ICA Inlet Outlet PCA Outlet Aneurysm PED Figure 6 - Percentage reductions in aneurysmal RMS velocity magnitude with respect to the untreated models for each growth stage under conditions of 2, 3, and 4 mL/s steady-state inflow rate. STAGE 3STAGE 1 STAGE 2 UNTREATEDTREATED Velocity Magnitude (m/s) Figure 4 - WSS distributions at 3 mL/s steady-state inflow rate for (top) untreated and (bottom) treated cases. Treated cases result in 86%, 83%, & 82% reduction in aneurysmal WSSavg at stages 1, 2, & 3, respectively. The ICA Inlet has been omitted from all views in Figures 3 and 4 for clarity purposes, however, a small portion of the ICA inlet is shown in Figure 5 so as to reveal the stream traces. Stage 1 is at 49 years of age, stage 2 is 445 days post stage 1, and stage 3 is 759 days post stage 2. (a) (b) (c)